CME Symposium: Diabetes Therapies and Cardiovascular Risk Reduction : Taking a Closer Look at SGT 2 Inhibitors and GLP-1 Receptor Agonists

This CME Symposium takes place on October 9, 2018, from 6:30 PM - 8:00PM at the New Orleans Downtown Marriott at the Convention Center, Blaine Kern Ballroom, 859 Convention Center Boulevard, New Orleans, Louisiana
2018 AAFP CME Symposium
2018 AAFP CME Symposium
NEW ORLEANS - Aug. 24, 2018 - PRLog -- Diabetes Therapies and Cardiovascular Risk Reduction: Taking a Closer Look at SGLT2 inhibitors and GLP-1 Receptor Agonists


Jay Shubrook , DO , FAAFP

Professor of Medicine
Touro University California
Vallejo, California


Lawrence Leiter, MD

Professor of Medicine and Nutritional Sciences
University of Toronto
Toronto, Canada

Darren McGuire, MD, MHSc
Professor of Internal Medicine
University of Texas Southwestern Medical Center
Dallas, Texas

Click to Register Online

Position statements for the management of hyperglycemia in patients with type 2 diabetes (T2D) are placing increasing emphasis on sodium glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs). The American Association of Clinical Endocrinologists (AACE)/American College of Endocrinology (ACE) consensus statement suggests GLP-1 RAs and SGLT2 inhibitors as second and third agents, respectively, after metformin monotherapy. The American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) have released a draft of their 2018 update on the management of hyperglycemia in patients with T2D. In this draft (final version of the update to be released in the week prior to the AAFP FMX annual meeting), SGLT2 inhibitors and GLP-1 RAs are given very important roles in treatment, due to their cardiovascular and renal benefits demonstrated in cardiovascular outcome trials (CVOTs). In this program, an expert faculty (Chair Dr. Jay Shubrook, Dr. Lawrence Leiter, and Dr. Darren McGuire) will discuss the new recommendations for management of hyperglycemia, the roles for SGLT2 inhibitors and GLP1 RAs, and the importance of identifying atherosclerotic cardiovascular disease (ASCVD) for consideration of diabetes drugs. The numerous recently completed CVOTs and large multinational studies with these therapies will be interpreted. Best practices for using these agents will be demonstrated using case studies and explained with take-home tips for clinical practice.

Voxmedia International gratefully acknowledges the educational grant provided by AstraZeneca Pharmaceuticals LP.

This program was developed for the education of family physicians and other healthcare professionals.

Pre-registration is for planning purposes only.

For additional CME activities and online cme courses visit CMEPlanet

Tags:Free Cme, Cme, Medical Education, Cardiologists, Cardiology, Diabetes, Diabetes Therapies
Industry:Education, Free, Medical
Location:New Orleans - Louisiana - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share